var data={"title":"Travoprost: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Travoprost: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7088?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=travoprost-drug-information\" class=\"drug drug_general\">see &quot;Travoprost: Drug information&quot;</a> and <a href=\"topic.htm?path=travoprost-patient-drug-information\" class=\"drug drug_patient\">see &quot;Travoprost: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230214\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Travatan Z</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230215\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Travoprost Z;</li>\n      <li>IZBA;</li>\n      <li>Sandoz-Travoprost;</li>\n      <li>Teva-Travoprost Z Ophthalmic Solution;</li>\n      <li>Travatan Z</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1040327\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Ophthalmic Agent, Antiglaucoma</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Prostaglandin, Ophthalmic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1040351\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=travoprost-drug-information\" class=\"drug drug_general\">see &quot;Travoprost: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not exceed once-daily dosing (may decrease IOP-lowering effect).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Elevated intraocular pressure: </b>Ophthalmic: Children and Adolescents: Limited data available: 1 drop into affected eye(s) once daily in the evening (Yanovich, 2008) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Elevated intraocular pressure: </b>Ophthalmic: Instill 1 drop into affected eye(s) once daily in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adolescents &ge;16 years and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments are unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adolescents &ge;16 years and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments are unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230196\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Travatan Z: 0.004% (2.5 mL, 5 mL) [benzalkonium free; contains cremophor el, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.004% (2.5 mL [DSC], 5 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230184\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1040354\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Travoprost may be used with other eye drops to lower intraocular pressure. If using more than one ophthalmic product, wait at least 5 minutes in between application of each medication. Apply gentle pressure to lacrimal sac immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration to decrease systemic absorption of ophthalmic drops (Urtti, 1993; Zimmerman, 1982). Remove contact lenses prior to administration and wait 15 minutes (after administration) before reinserting. Avoid contact of bottle tip with skin or eye; ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230212\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 2&deg;C and 25&deg;C (36&deg;F and 77&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1040328\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (FDA approved in ages &ge;16 years and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230240\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Travatan may be confused with Xalatan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230239\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, bradycardia, chest pain, hypertension, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, depression, foreign body sensation of eye, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Hyperpigmentation of eyelashes, increased growth in number of eyelashes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypercholesterolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dyspepsia, gastrointestinal distress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Prostatic disease, urinary incontinence, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthritis, back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, crusting of eyelid, decreased visual acuity, dry eye syndrome, eye discomfort, eye pain, eye pruritus, hyperpigmentation of eyelids, increased eyelash length, increased eyelash thickness, iris discoloration, keratitis, lacrimation, ocular hyperemia, ophthalmic inflammation, photophobia, subconjunctival hemorrhage, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, flu-like symptoms, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, arthralgia, asthma, bacterial keratitis (due to solution contamination), cardiac arrhythmia, chest discomfort, corneal edema, cystoid macular edema, diarrhea, dyspnea, dysuria, enophthalmos, epistaxis, erythema, insomnia, iritis, macular edema, musculoskeletal pain, nausea, prostate specific antigen increase, pruritus, tachycardia, tinnitus, uveitis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230202\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to travoprost or any component of the formulation; pregnancy or women attempting to become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230188\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May permanently change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes. In addition, may increase the length, thickness, and/or number of eyelashes (may vary between eyes); changes occur slowly and may not be noticeable for months or years. Long-term consequences and potential injury to eye are not known.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with intraocular inflammation (eg, uveitis), aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Safety and efficacy have not been determined for use in patients with angle-closure-, inflammatory-, or neovascular glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Remove contact lens prior to instillation; may reinsert 15 minutes following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use in pediatric patients (&lt;16 years of age) is not recommended due to possible safety issues of increased pigmentation following long-term chronic use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300163\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223400\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=97564&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230193\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230205\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies following systemic administration. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230187\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A selective FP prostanoid receptor agonist which lowers intraocular pressure by increasing trabecular meshwork and outflow</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230201\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Absorbed via cornea; plasma levels &lt;10 pg/mL within 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hydrolyzed by esterases in the cornea to active free acid; systemically; the free acid is metabolized to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 45 minutes (range: 17 to 86 minutes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230204\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Travatan Z Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.004% (2.5 mL): $204.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F230206\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Avatan (LK);</li>\n      <li>Avost (BD);</li>\n      <li>Avro (BD);</li>\n      <li>Hlavtan (UA);</li>\n      <li>Izba (IE, TH);</li>\n      <li>Trapost (BD);</li>\n      <li>Travatan (AE, AR, AT, AU, BE, BG, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VE, VN, ZA);</li>\n      <li>Travatanz (JP);</li>\n      <li>Travotan (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Izba (travoprost) [prescribing information]. Fort Worth, TX: Alcon Laboratories, Inc; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR and Meyer SM, &quot;Use of Ophthalmic Medications in Pregnant and Nursing Women,&quot; <i>Am J Ophthalmol</i>, 1988, 106(5):616-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travoprost-pediatric-drug-information/abstract-text/2903673/pubmed\" target=\"_blank\" id=\"2903673\">2903673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Travatan Z (travoprost) [prescribing information]. Fort Worth, TX: Alcon Laboratories, Inc; September 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travoprost-pediatric-drug-information/abstract-text/8100087/pubmed\" target=\"_blank\" id=\"8100087\">8100087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanovitch TL, Enyedi LB, Schotthoeffer EO, Freedman SF. Travoprost in children: adverse effects and intraocular pressure response. <i>J AAPOS</i>. 2009;13(1):91-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travoprost-pediatric-drug-information/abstract-text/19233013/pubmed\" target=\"_blank\" id=\"19233013\">19233013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984; 102(4):551-553. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travoprost-pediatric-drug-information/abstract-text/6704011 /pubmed\" target=\"_blank\" id=\"6704011 \">6704011 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 97564 Version 34.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F230214\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F230215\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1040327\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1040351\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F230196\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F230184\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1040354\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F230212\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1040328\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F230240\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F230239\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F230202\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F230188\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300163\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223400\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F230193\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F230205\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F230187\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F230201\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F230204\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F230206\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/97564|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=travoprost-drug-information\" class=\"drug drug_general\">Travoprost: Drug information</a></li><li><a href=\"topic.htm?path=travoprost-patient-drug-information\" class=\"drug drug_patient\">Travoprost: Patient drug information</a></li></ul></div></div>","javascript":null}